Semax regulatory status: Category 2 and the reclassification path
Semax left FDA Category 2 in April 2026 — but removal isn't approval to compound.
TL;DR
- Semax's regulatory status changed in April 2026 — the FDA removed it from Category 2.
- Removal isn't approval. Semax still needs a Pharmacy Compounding Advisory Committee (PCAC) recommendation.
- The PCAC discusses Semax on July 24, 2026. No decision has been announced yet.
Semax regulatory status: removed from Category 2, still short of compounding approval
Semax is a synthetic peptide (in plain English: a lab-made chain of amino acids, protein's building blocks). It comes from adrenocorticotropic hormone, or ACTH (in plain English: a stress hormone your pituitary gland releases). Developed in Russia, Semax has never been approved by the U.S. Food and Drug Administration (FDA) (Eremin et al., Neurochemical Research, 2005). In late 2023, the FDA flagged Semax and 18 other peptides as Category 2 under Section 503A (in plain English: the FDA rule for custom-mixed pharmacy medicines) — a safety-risk flag. On April 15, 2026, Semax was one of 12 peptides the FDA confirmed removed (FDA, 2026).
How Semax's Category 2 removal and PCAC review fit together
Think of FDA compounding approval as two checkpoints. The first is Category placement, a safety-risk screen; Semax cleared it April 15, 2026. The second is a recommendation from the Pharmacy Compounding Advisory Committee (PCAC — in plain English: the expert panel that votes on which substances pharmacies may compound). The PCAC discusses Semax on July 24, 2026 (FDA, 2026). Clearing Category 2 opened a door; Semax hasn't walked through it yet.
Who asks about Semax's regulatory status
People ask after reading that Semax "isn't Category 2 anymore" and wondering if that makes it legal to buy compounded. Others are tracking the broader reclassification wave and want to know where things stand.
What the research says about Semax and its path to compounding
Semax's underlying science and its regulatory status are separate tracks. Published research comes mostly from animal studies in Russia, linking Semax to dopamine and serotonin activity in the brain (Eremin et al., Neurochemical Research, 2005). Semax was removed from Category 2 alongside BPC-157, TB-500, MOTS-c, GHK-Cu, Melanotan II, and PEG-MGF (FDA, 2026).
What to know before considering Semax's regulatory status
Semax isn't available from a licensed U.S. pharmacy, and that won't change automatically. The PCAC's July 24 discussion could lead to a recommendation, but no outcome has been announced yet. Even if Semax clears review, compounded Semax still won't be FDA-approved — 503A pharmacies compound from bulk substances, not approved products. Anyone considering Semax should wait for a licensed clinician and a confirmed pathway.
The Halftime POV
We'd rather explain what changed than let a "removed from Category 2" headline do the work. That distinction — cleared one review, not yet cleared for compounding — is the whole story. We'll update this page the day the PCAC votes.
Related reading:
- PCAC advisory committee, explained
- Why some peptides are still stuck in Category 2
- PCAC July 2026 meeting: what's on the agenda
- Reading the FDA's PCAC briefing documents
- The second PCAC meeting: five more peptides under review for 2027
FAQ
Q: Is Semax legal in the US? A: Semax is not FDA-approved, and no compounding pharmacy can legally sell it today. It was removed from FDA Category 2 in April 2026, which lifted the significant-safety-risk flag, but it still needs a separate Pharmacy Compounding Advisory Committee review before pharmacies can compound it.
Q: What does removal from Category 2 mean for Semax? A: It means the FDA no longer treats Semax as a flagged safety risk pending review, because its Category 2 nomination was withdrawn. It does not mean Semax was added to the approved 503A compounding list — that requires its own Pharmacy Compounding Advisory Committee recommendation.
Q: When will Semax be reclassified? A: The Pharmacy Compounding Advisory Committee is scheduled to discuss Semax-related bulk drug substances on July 24, 2026. As of July 20, 2026, no vote has happened and no outcome has been announced.
Q: Is Semax FDA approved? A: No. Semax has never been approved by the FDA for any use in the United States. Even if it eventually clears compounding review, compounded Semax would still not itself be an FDA-approved drug product.
Q: What is the Pharmacy Compounding Advisory Committee reviewing the week of July 23, 2026? A: On July 23, 2026, the committee discusses BPC-157, KPV, TB-500, and MOTS-c. On July 24, 2026, it discusses Emideltide (DSIP), Semax, and Epitalon.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — FDA
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA
- Eremin KO et al., "Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents," Neurochemical Research (2005)
Frequently asked questions
Is Semax legal in the US?
Semax is not FDA-approved, and no compounding pharmacy can legally sell it today. It was removed from FDA Category 2 in April 2026, which lifted the significant-safety-risk flag, but it still needs a separate Pharmacy Compounding Advisory Committee review before pharmacies can compound it.
What does removal from Category 2 mean for Semax?
It means the FDA no longer treats Semax as a flagged safety risk pending review, because its Category 2 nomination was withdrawn. It does not mean Semax was added to the approved 503A compounding list — that requires its own Pharmacy Compounding Advisory Committee recommendation.
When will Semax be reclassified?
The Pharmacy Compounding Advisory Committee is scheduled to discuss Semax-related bulk drug substances on July 24, 2026. As of July 20, 2026, no vote has happened and no outcome has been announced.
Is Semax FDA approved?
No. Semax has never been approved by the FDA for any use in the United States. Even if it eventually clears compounding review, compounded Semax would still not itself be an FDA-approved drug product.
What is the Pharmacy Compounding Advisory Committee reviewing the week of July 23, 2026?
On July 23, 2026, the committee discusses BPC-157, KPV, TB-500, and MOTS-c. On July 24, 2026, it discusses Emideltide (DSIP), Semax, and Epitalon.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.